Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety-relevant label-supported elements (indications, mechanism as PTHrP(1-34) analog to PTH1R, dosing, and some administration) align with the provided excerpts, but multiple claims are unsupported by the excerpts, and at least one claim likely conflicts or is not assessable with the provided label text (generic availability).
Category Scores
Accurate Statements
Abaloparatide is a medication approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
1.1
Abaloparatide is indicated for men with osteoporosis at high risk for fracture.
1.2
Abaloparatide is a synthetic peptide analog of human parathyroid hormone-related peptide (PTHrP).
12.1 (PTHrP(1-34) analog)
Abaloparatide stimulates bone formation by binding to the PTH type 1 receptor, primarily on osteoblasts.
12.1 (acts as agonist at PTH1R; once-daily administration stimulates new bone formation). Note: 'primarily on osteoblasts' is not explicitly supported in the provided excerpts.
Binding to the PTH type 1 receptor promotes bone metabolism and increases bone mineral density.
12.1 (stimulates new bone formation); 14.2 (increases BMD). Note: 'promotes bone metabolism' is not explicit in excerpts.
Unsupported Statements
The generic name for Tymlos is abaloparatide.
No label excerpt provided explicitly states 'generic name'.
Tymlos is manufactured by Radius Health, Inc.
No label excerpt provided includes manufacturer information.
There are no generic versions of abaloparatide available on the market.
No label excerpt provided addresses market availability of generics.
Abaloparatide stimulates bone formation by binding to the PTH type 1 receptor, primarily on osteoblasts.
'primarily on osteoblasts' is not stated in the supplied label excerpts.
Binding to the PTH type 1 receptor promotes bone metabolism and increases bone mineral density.
'promotes bone metabolism' is not explicitly stated in the supplied excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No AI claim evaluated included the specific labeled dosing instruction (80 mcg SC once daily) or administration technique (periumbilical abdomen; rotate site; do not administer IV/IM) in the claim list provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about generic availability/manufacturer do not directly change clinical safety, but at least one mechanistic detail ('primarily on osteoblasts') and one market claim are unsupported by provided excerpts. Indication claims are supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA-label excerpts (generic-name statement, manufacturer, lack of generics, and mechanistic sub-detail about osteoblast predominance).
Suggested Improvement
Remove or rephrase unsupported claims unless the full label (or specified sections) explicitly supports them; limit mechanism description to what is stated in 12.1 and indications to 1.1/1.2.